pneumococcal polysaccharide [serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, 33F] (20-valent) vaccine

Trials studying pneumococcal polysaccharide [serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, 33F] (20-valent) vaccine

• phase1A Study of V118E in Healthy Participants (V118E-003)recruitingn=126
• phase3BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babiesrecruitingn=6,000
• phase3Study of a 4-Dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Ageactive not recruitingn=1,714
• phase3Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Ageactive not recruitingn=2,360
• phase3Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Ageactive not recruitingn=580
• phase3Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infantscompletedn=1,196
• phase1A Study of V118 Formulation C (V118C) in Healthy Participants (V118C-001)completedn=65
• phase2A Phase 2 Study to Evaluate the Safety, Tolerability, and Immune Response of AFX3772 Vaccine in Healthy Infantscompletedn=388